Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma - Sonneveld, Pieter; Dimopoulos, Meletios A.; Boccadoro, Mario; Quach, Hang; Ho, P. Joy; Beksac, Meral; Hulin, Cyrille; Antonioli, Elisabetta; Leleu, Xavier; Mangiacavalli, Silvia; Perrot, Aurore; Cavo, Michele; et al. (The New England journal of medicine, 2024)
Keywords: Adverse events; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - adverse effects; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bone marrow; Bortezomib; Bortezomib - administration & dosage; Bortezomib - adverse effects; Cancer therapies; CD38 antigen; Death; Dexamethasone; Dexamethasone - administration & dosage; Dexamethasone - adverse effects; Disease Progression; Hematology; Humans; Immunotherapy; Induction therapy; Inhibitor drugs; Lenalidomide - administration & dosage; Lenalidomide - adverse effects; Leukemia; Lymphoma; Minimal residual disease; Monoclonal antibodies; Multiple myeloma; Multiple Myeloma - drug therapy; Neutropenia; Oncology; Risk assessment; Survival; Targeted cancer therapy; Thrombocytopenia; Transplantation; Treatments in Oncology